



NATIONAL  
QUALITY FORUM

## Memo

TO: Executive Committee  
 FR: Helen Burstin, Chief Scientific Officer  
 Marcia Wilson, Senior Vice President, Quality Measurement  
 RE: Ratification of Measures for the Cardiovascular Project 2016-2017  
 DA: November 21, 2016

### ACTION REQUIRED

The Executive Committee is asked to ratify the Consensus Standards Approval Committee's (CSAC) recommendation to endorse measures for the current phase of the Cardiovascular Project. All recommended measures approved by the membership and the CSAC are listed below.

#### Measures Evaluated:

The [Cardiovascular Project Standing Committee](#) evaluated six measures: two new measures and four measures undergoing maintenance review against NQF's standard measure evaluation criteria.

#### *Consensus Process*

Standing Committee: The Committee recommended four measures and two measures were not recommended for endorsement.

Member Voting: A total of eight member organizations voted on the measures. All of the recommended measures were approved, with 88% approval or higher. No votes were received from the Consumer, Public/Community Health Agency or Supplier/Industry Councils.

CSAC: The CSAC voted to recommend four measures for endorsement. The CSAC memo and Member voting results for this project may be accessed at this [link](#); the project report may be accessed at this [link](#).

#### *Measures Recommended:*

- [0066](#): **Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy - Diabetes or Left Ventricular Systolic Dysfunction (LVEF < 40%).** Percentage of patients aged 18 years and older with a diagnosis of coronary artery disease seen within a 12 month period who also have diabetes OR a current or prior Left Ventricular Ejection Fraction (LVEF) < 40% who were prescribed ACE inhibitor or ARB therapy.
- [0076](#): **Optimal Vascular Care.** Percentage of patients 18-75 years of age who had a diagnosis of ischemic vascular disease (IVD) and whose IVD was optimally managed during the measurement period as defined by achieving ALL of the following: Blood pressure less than 140/90 mmHg, On a statin medication, unless allowed contraindications or exceptions are present, Non-tobacco user, On daily aspirin or anti-platelet medication, unless allowed contraindications or exceptions are present.

- [0290](#): **Median Time to Transfer to Another Facility for Acute Coronary Intervention.** Median time from emergency department (ED) arrival to time of transfer to another facility for acute coronary intervention (ACI) for ST-segment myocardial infarction (STEMI) patients that require a percutaneous coronary intervention (PCI).
- [2906](#): **Coronary Artery Disease (CAD): Beta-Blocker Therapy-Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%) – Legacy eMeasure.** Percentage of patients aged 18 years and older with a diagnosis of coronary artery disease seen within a 12 month period who also have a prior MI or a current or prior LVEF <40% who were prescribed beta-blocker therapy.

*Measures Not Recommended:*

- [0288](#): **Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival.** Percentage of Emergency Department (ED) acute myocardial infarction (AMI) patients with ST-segment elevation on the electrocardiogram (ECG) closest to arrival time receiving fibrinolytic therapy during the ED stay and having a time from ED arrival to fibrinolysis of 30 minutes or less.
- [2939](#): **Statin Therapy in Patients with Clinical Atherosclerotic Disease.** Percentage of patients 18-75 year of age with clinical atherosclerotic cardiovascular disease (ASCVD) who were offered moderate-to high-intensity statin.